News & Events – Page 6 – Sumitovant

Select Company

November 25, 2019Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
November 19, 2019Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
November 18, 2019Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
November 12, 2019Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019
October 31, 2019Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
October 21, 2019Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
October 17, 2019First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms
October 17, 2019Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
October 10, 2019Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
September 06, 2019Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
« Previous 1 … 4 5 6 7 8 Next »